JANX: Janux Therapeutics, Inc. Common Stock Company Profile & Statistics

Janux Therapeutics, Inc. Common Stock Profile

About

Janux Therapeutics Inc. is a biopharmaceutical company. It involved in developing novel T cell engager immunotherapies. Janux Therapeutics Inc. is based in LA JOLLA, Calif.

Info & Links

CEO

David Campbell

Headquarters

10955 Vista Sorrento Parkway, Suite 200
San Diego, CA 92130, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

Employees

Janux Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

1.44B

Enterprise Value

1.39B

Enterprise Value/EBITDA(ttm)

-8.81

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

108.90

Price to Book(mrq)

1.40

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

25.00%

Operating Margin(ttm)

Profit Margin(ttm)

-1597.89%

Return on Equity(ttm)

-9.29%

Return on Invested Capital(ttm)

-11.99%

Return on Assets(ttm)

-8.89%

Income Statement

Revenue(ttm)

439.00K

Revenue Per Share(ttm)

0.01

Gross Profit(ttm)

439.00K

EBITDA(ttm)³

-158.05M

Net Income Available to Common(ttm)

-105.64M

Diluted EPS(ttm)

-1.36

Share Statistics

Beta (5Y Monthly)

2.86

52-Week Change

-52.92%

S&P 500 52-Week Change

17.44%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

60.09M

Dividend Yield

0.00%

Float⁴

54.38M

% Held by Insiders

8.10%

% Held by Institutions

75.39%

Balance Sheet

Total Cash(mrq)

996.01M

Total Cash Per Share(mrq)

16.57

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

47.03%

Quick Ratio(mrq)

58.47%

Book Value Per Share(mrq)

16.70

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.66

Free Cash Flow(ytd)

-41.68M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

JANX

Janux Therapeutics, Inc. Common Stock